In order to develop an active immunotherapy against PD and to reduce the risk of T-cell activation, Mandler et al. used short peptides that were designed to bind to the C-terminus domain (110–130 aa) and hence did not represent the native epitope of full-length α-synuclein [23]. Here, SNCA is linked to Parkinson disease.